PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study

  • PhaseBio Pharmaceuticals Inc PHAS has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old.
  • The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plc's AZN Brilinta (ticagrelor) and low-dose aspirin. 
  • Bentracimab is a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
  • The Phase 2b trial achieved its primary endpoint of reversing ticagrelor's inhibition of platelet function in actively treated subjects versus placebo.
  • Bentracimab is currently being evaluated in the REVERSE-IT Phase 3 trial in approximately 200 participants.
  • A prespecified interim analysis from the REVERSE-IT trial will be presented on November 15 at the American Heart Association's Scientific Sessions 2021. 
  • PhaseBio is targeting marketing application submission to the FDA in mid-2022.
  • Also Read: CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal.
  • Price Action: PHAS shares are down 3.21% at $3.92 during the market session on the last check Wednesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.